Cargando…
PARP Inhibitors as Monotherapy in Daily Practice for Advanced Prostate Cancers
Despite recent improvements in survival, metastatic castration-resistant prostate cancers (mCRPCs) remain lethal. Alterations in genes involved in the homologous recombination repair (HRR) pathway are associated with poor prognosis. Poly-ADP-ribose polymerase (PARP) inhibitors (PARPis) have demonstr...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8952857/ https://www.ncbi.nlm.nih.gov/pubmed/35330059 http://dx.doi.org/10.3390/jcm11061734 |
_version_ | 1784675720521318400 |
---|---|
author | Teyssonneau, Diego Thiery-Vuillemin, Antoine Dariane, Charles Barret, Eric Beauval, Jean-Baptiste Brureau, Laurent Créhange, Gilles Fiard, Gaëlle Fromont, Gaëlle Gauthé, Mathieu Ruffion, Alain Renard-Penna, Raphaële Mathieu, Romain Sargos, Paul Rouprêt, Morgan Ploussard, Guillaume Roubaud, Guilhem |
author_facet | Teyssonneau, Diego Thiery-Vuillemin, Antoine Dariane, Charles Barret, Eric Beauval, Jean-Baptiste Brureau, Laurent Créhange, Gilles Fiard, Gaëlle Fromont, Gaëlle Gauthé, Mathieu Ruffion, Alain Renard-Penna, Raphaële Mathieu, Romain Sargos, Paul Rouprêt, Morgan Ploussard, Guillaume Roubaud, Guilhem |
author_sort | Teyssonneau, Diego |
collection | PubMed |
description | Despite recent improvements in survival, metastatic castration-resistant prostate cancers (mCRPCs) remain lethal. Alterations in genes involved in the homologous recombination repair (HRR) pathway are associated with poor prognosis. Poly-ADP-ribose polymerase (PARP) inhibitors (PARPis) have demonstrated anti-tumoral effects by synthetic lethality in patients with mCRPCs harboring HRR gene alterations, in particular BRCA2. While both olaparib and rucaparib have obtained government approvals for use, the selection of eligible patients as well as the prescription of these treatments within the clinical urology community are challenging. This review proposes a brief review of the rationale and outcomes of PARPi treatment, then a pragmatic vision of PARPi use in terms of prescription and the selection of patients based on molecular screening, which can involve potential genetic counseling in the case of associated germinal alterations. |
format | Online Article Text |
id | pubmed-8952857 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-89528572022-03-26 PARP Inhibitors as Monotherapy in Daily Practice for Advanced Prostate Cancers Teyssonneau, Diego Thiery-Vuillemin, Antoine Dariane, Charles Barret, Eric Beauval, Jean-Baptiste Brureau, Laurent Créhange, Gilles Fiard, Gaëlle Fromont, Gaëlle Gauthé, Mathieu Ruffion, Alain Renard-Penna, Raphaële Mathieu, Romain Sargos, Paul Rouprêt, Morgan Ploussard, Guillaume Roubaud, Guilhem J Clin Med Review Despite recent improvements in survival, metastatic castration-resistant prostate cancers (mCRPCs) remain lethal. Alterations in genes involved in the homologous recombination repair (HRR) pathway are associated with poor prognosis. Poly-ADP-ribose polymerase (PARP) inhibitors (PARPis) have demonstrated anti-tumoral effects by synthetic lethality in patients with mCRPCs harboring HRR gene alterations, in particular BRCA2. While both olaparib and rucaparib have obtained government approvals for use, the selection of eligible patients as well as the prescription of these treatments within the clinical urology community are challenging. This review proposes a brief review of the rationale and outcomes of PARPi treatment, then a pragmatic vision of PARPi use in terms of prescription and the selection of patients based on molecular screening, which can involve potential genetic counseling in the case of associated germinal alterations. MDPI 2022-03-21 /pmc/articles/PMC8952857/ /pubmed/35330059 http://dx.doi.org/10.3390/jcm11061734 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Teyssonneau, Diego Thiery-Vuillemin, Antoine Dariane, Charles Barret, Eric Beauval, Jean-Baptiste Brureau, Laurent Créhange, Gilles Fiard, Gaëlle Fromont, Gaëlle Gauthé, Mathieu Ruffion, Alain Renard-Penna, Raphaële Mathieu, Romain Sargos, Paul Rouprêt, Morgan Ploussard, Guillaume Roubaud, Guilhem PARP Inhibitors as Monotherapy in Daily Practice for Advanced Prostate Cancers |
title | PARP Inhibitors as Monotherapy in Daily Practice for Advanced Prostate Cancers |
title_full | PARP Inhibitors as Monotherapy in Daily Practice for Advanced Prostate Cancers |
title_fullStr | PARP Inhibitors as Monotherapy in Daily Practice for Advanced Prostate Cancers |
title_full_unstemmed | PARP Inhibitors as Monotherapy in Daily Practice for Advanced Prostate Cancers |
title_short | PARP Inhibitors as Monotherapy in Daily Practice for Advanced Prostate Cancers |
title_sort | parp inhibitors as monotherapy in daily practice for advanced prostate cancers |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8952857/ https://www.ncbi.nlm.nih.gov/pubmed/35330059 http://dx.doi.org/10.3390/jcm11061734 |
work_keys_str_mv | AT teyssonneaudiego parpinhibitorsasmonotherapyindailypracticeforadvancedprostatecancers AT thieryvuilleminantoine parpinhibitorsasmonotherapyindailypracticeforadvancedprostatecancers AT darianecharles parpinhibitorsasmonotherapyindailypracticeforadvancedprostatecancers AT barreteric parpinhibitorsasmonotherapyindailypracticeforadvancedprostatecancers AT beauvaljeanbaptiste parpinhibitorsasmonotherapyindailypracticeforadvancedprostatecancers AT brureaulaurent parpinhibitorsasmonotherapyindailypracticeforadvancedprostatecancers AT crehangegilles parpinhibitorsasmonotherapyindailypracticeforadvancedprostatecancers AT fiardgaelle parpinhibitorsasmonotherapyindailypracticeforadvancedprostatecancers AT fromontgaelle parpinhibitorsasmonotherapyindailypracticeforadvancedprostatecancers AT gauthemathieu parpinhibitorsasmonotherapyindailypracticeforadvancedprostatecancers AT ruffionalain parpinhibitorsasmonotherapyindailypracticeforadvancedprostatecancers AT renardpennaraphaele parpinhibitorsasmonotherapyindailypracticeforadvancedprostatecancers AT mathieuromain parpinhibitorsasmonotherapyindailypracticeforadvancedprostatecancers AT sargospaul parpinhibitorsasmonotherapyindailypracticeforadvancedprostatecancers AT roupretmorgan parpinhibitorsasmonotherapyindailypracticeforadvancedprostatecancers AT ploussardguillaume parpinhibitorsasmonotherapyindailypracticeforadvancedprostatecancers AT roubaudguilhem parpinhibitorsasmonotherapyindailypracticeforadvancedprostatecancers AT parpinhibitorsasmonotherapyindailypracticeforadvancedprostatecancers |